Who we are
Our Functional Genomics Centre (FGC) is a unique collaboration between AstraZeneca and Cancer Research Horizons. We created a world-leading centre of excellence in genetic screens, cancer models, CRISPR vector design and computational approaches to big data. Our goal is to identify novel targets and drug resistance mechanisms to help develop new cancer medicines.
What we do
We collaborate with leading researchers to deliver pooled CRISPR screens that identify and validate new drug targets and approaches that will change the cancer landscape.
Our state-of-the-art institute leverages the combined global strengths of Cancer Research UK’s world-class scientific network and AstraZeneca’s oncology drug discovery and development experience to drive scientific innovation.
We identify innovative approaches to tackle traditionally hard-to-treat cancers by deepening our understanding of key drivers of cancer and resistance mechanisms.
The key to our success is researcher autonomy. We empower you to explore bold new ideas without restraint.
We work with AstraZeneca, sharing resources and expertise, but all Cancer Research Horizons projects are independent and resulting data will remain confidential and unencumbered.
What we offer
Our CRISPR expertise
We can run pooled CRISPR screens, supporting everything from initial assay design, Cas9 cell line generation, to bioinformatic analysis and interpretation of the screen data results.
We use an optimised CRISPR platform for pooled CRISPR knockout and activation screening that enables the identification of genome-wide genetic vulnerabilities. Our specialist CRISPR screen areas:
- Essentiality and drug gene-interaction
- Primary immune cells
- Co-culture
- 3D models
- In-vivo
Data correct as of December 2024.
Collaborating with the Functional Genomics Centre provided access to advanced CRISPR screening capabilities, expert assay design and rapid results. Their team's efficiency and collaborative spirit made the project a success.
Our cutting-edge research tools
| Pooled sgRNA screening |
|
| Bioinformatics and data analysis |
|
| Pooled sgRNA library cloning |
|
| Technology development | Our active technology development programme evaluates new CRISPR technologies, enabling us to perform more complex CRISPR screens and identify disease-relevance drug targets. Our development areas include:
|
Access guidelines and costing
While we cover the majority of the collaboration costs, we request a contribution from the collaborator to help sustain part of the expenses. Costs for projects entering the FGC starts at £4,000 (not including VAT) per genome wide CRISPR knock-out screen in a established cancer cell line with standard characteristics (i.e. normal growth rates, media and serum requirements. Exact costs will vary depending on the complexity of the experimental setup). This cost will include:
- One genome wide screen in a established cancer cell line
- Two technical replicates
- Next Generation Sequencing
- Standard bioinformatic analysis
Deadlines
Proposals are reviewed quarterly. The next deadline to submit your application is 9 June 2026.
Eligibility
To access the FGC's screening capabilities you should be either:
- A Cancer Research UK grant holder
- A researcher working at a Cancer Research UK Institute or Centre, benefitting from Cancer Research UK funding.
If you are unsure of your eligibility, please contact [email protected]
Our experts have the skills and technology to make your project a success
If your research could benefit from access to novel, state-of-the-art CRISPR technology, we would love to work with you.
The Functional Genomics Centre's team have helped identify networks of genes we didn't predict, shaping our research strategy for the next years.
Our translational science
Additional support
We identify, develop and commercialise promising ideas into successful cancer therapeutics, diagnostics and enabling technologies.
Speak to our team of experts
